J. Slaton

发表

A three-layer competition-based giant magnetoresistive assay for direct quantification of endoglin from human urine.

Jian-Ping Wang, Ying Jing, Jianping Wang, 2011, Analytical chemistry.

Phosphatidylserine targeted single-walled carbon nanotubes for photothermal ablation of bladder cancer

D. Resasco, P. Hauser, C. Davis, 2018, Nanotechnology.

Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma.

Steven J. M. Jones, Benjamin J. Raphael, Mark D. M. Leiserson, 2016, The New England journal of medicine.

Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma.

A. El‐Naggar, C. Dinney, I. Fidler, 2001, The American journal of pathology.

Alvimopan, a peripherally acting μ-opioid receptor antagonist, is associated with reduced costs after radical cystectomy: economic analysis of a phase 4 randomized, controlled trial.

Sam S. Chang, R. Karnes, W. Sexton, 2014, The Journal of urology.

Protein Kinase CK2 in Health and Disease

G. Unger, J. H. Trembley, K. Ahmed, 2009, Cellular and Molecular Life Sciences.

Protein kinase CK2--a key suppressor of apoptosis.

G. Unger, K. Ahmed, J. Slaton, 2008, Advances in enzyme regulation.

Emergence of protein kinase CK2 as a key target in cancer therapy

C. Van Waes, Zhong Chen, G. Unger, 2010, BioFactors.

Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy.

C. Dinney, L. Pagliaro, J. Slaton, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Conservative management of suspected bladder rupture after augmentation enterocystoplasty.

J. Slaton, K. Kropp, 1994, The Journal of urology.

Use of tumor necrosis factor-alpha-coated gold nanoparticles to enhance radiofrequency ablation in a translational model of renal tumors.

J. Bischof, J. Slaton, S. Schmechel, 2010, Urology.

Tumor length and location of cancer on biopsy predict for side specific extraprostatic cancer extension.

P. Troncoso, R. Babaian, K. Okihara, 2004, The Journal of urology.

Medicinal mushrooms: A contemporary perspective

L. Standish, J. Slaton, C. Torkelson, 2007 .

Surgical management of renal cell carcinoma associated with complex inferior vena caval thrombi.

C. Wood, S. Swisher, C. Dinney, 2003, Urologic oncology.

Protein kinase CK2 as regulator of cell survival: implications for cancer therapy.

G. Unger, K. Ahmed, J. Slaton, 2004, Current cancer drug targets.

Targeting CK2 for cancer therapy.

G. Unger, K. Ahmed, J. Slaton, 2005, Anti-cancer drugs.

Disparities in long-term radiographic follow-up after cystectomy for bladder cancer: Analysis of the SEER-Medicare database

D. Dynda, J. Slaton, S. Alanee, 2016, Urology annals.

Second prize: Comprehensive proteomic analysis of human calcium oxalate monohydrate kidney stone matrix.

M. Monga, J. Slaton, LeeAnn Higgins, 2008, Journal of endourology.

CK2 signaling in androgen‐dependent and ‐independent prostate cancer

G. Unger, K. Ahmed, J. Slaton, 2006, Journal of cellular biochemistry.

Laser prostatectomy versus transurethral resection for treating benign prostatic obstruction: a systematic review.

T. Wilt, R. MacDonald, J. Slaton, 2003, The Journal of urology.

Effects of Soy Protein Isolate Consumption on Prostate Cancer Biomarkers in Men With HGPIN, ASAP, and Low-Grade Prostate Cancer

J. Slaton, W. Thomas, M. Kurzer, 2007, Nutrition and cancer.

Isoflavone-rich soy protein isolate suppresses androgen receptor expression without altering estrogen receptor-beta expression or serum hormonal profiles in men at high risk of prostate cancer.

J. Slaton, W. Thomas, M. Kurzer, 2007, The Journal of nutrition.

Soy protein isolate increases urinary estrogens and the ratio of 2:16α‐hydroxyestrone in men at high risk of prostate cancer

J. Slaton, W. Thomas, M. Kurzer, 2007, The Journal of nutrition.

Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis.

C. Dinney, W. Benedict, T. Karashima, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

The prognostic value of angiogenesis and metastasis-related genes for progression of transitional cell carcinoma of the renal pelvis and ureter.

P. Tamboli, C. Dinney, T. Shuin, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

CK2: A key player in cancer biology

G. Unger, J. H. Trembley, K. Ahmed, 2009 .

Correlation of metastasis related gene expression and relapse-free survival in patients with locally advanced bladder cancer treated with cystectomy and chemotherapy.

R. Millikan, B. Czerniak, C. Dinney, 2004, The Journal of urology.

Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma.

P. Pisters, B. Mian, L. Pisters, 2002, The Journal of urology.

Elevation of dipeptidylpeptidase iv activities in the prostate peripheral zone and prostatic secretions of men with prostate cancer: possible prostate cancer disease marker.

Michael J. Wilson, J. Slaton, N. Wasserman, 2005, The Journal of urology.

Differential expression of progression-related genes in the evolution of superficial to invasive transitional cell carcinoma of the bladder.

H. Grossman, B. Czerniak, C. Dinney, 2001, Oncology reports.

Nephrectomy and vena caval thrombectomy in patients with metastatic renal cell carcinoma.

C. Dinney, J. Nesbitt, L. Pisters, 1997, Urology.

Challenges and potential solutions to meeting accrual goals in a Phase II chemoprevention trial for prostate cancer.

J. Pow-Sang, K. Egan, M. Schell, 2012, Contemporary clinical trials.

Dipeptidylpeptidase IV activities in prostatic secretions.

Michael J. Wilson, J. Slaton, N. Wasserman, 2003, Advances in experimental medicine and biology.

Timely delivery of biological therapy after cytoreductive nephrectomy in carefully selected patients with metastatic renal cell carcinoma.

C. Dinney, J. Slaton, D. Swanson, 1998, The Journal of urology.

Repeated I ntravesical I nstillations o f a n A denoviral V ector i n Patients W ith L ocally A dvanced B ladder C ancer: A P hase I Study o f p53 Gene T herapy

C. Dinney, L. Pagliaro, J. Slaton, 2003 .

P53 in bladder cancer: mechanism of action, prognostic value, and target for therapy.

C. Dinney, W. Benedict, J. Slaton, 2001, Urology.

Protein Kinase CK2 in Health and Disease

G. Unger, J. H. Trembley, K. Ahmed, 2009, Cellular and Molecular Life Sciences.

Role for toll-like receptor 4 in TNF-alpha secretion by murine macrophages in response to polysaccharide Krestin, a Trametes versicolor mushroom extract.

J. Slaton, C. A. Wenner, Daniel T. Sloper, 2010, Fitoterapia.

Alvimopan accelerates gastrointestinal recovery after radical cystectomy: a multicenter randomized placebo-controlled trial.

Sam S. Chang, R. Karnes, W. Sexton, 2014, European urology.

Contemporary treatment of low risk stage I non-seminomatous germ cell testicular tumors: a survey of the Society of Urologic Oncology.

J. Slaton, S. Alanee, A. Nicholson, 2012, Urologic oncology.

Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel.

C. Dinney, D. Hicklin, K. Inoue, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Matrix metalloproteinase and heparin-stimulated serine proteinase activities in post-prostate massage urine of men with prostate cancer.

Michael J. Wilson, J. Slaton, A. Sinha, 2017, Experimental and molecular pathology.

Downregulation of CK2 induces apoptosis in cancer cells – A potential approach to cancer therapy

G. Unger, K. Ahmed, J. Slaton, 2005, Molecular and Cellular Biochemistry.

Adjuvant approaches to enhance cryosurgery.

Raghav Goel, J. Bischof, G. Vercellotti, 2009, Journal of biomechanical engineering.

Contemporary morbidity from lymphadenectomy for penile squamous cell carcinoma: the M.D. Anderson Cancer Center Experience.

C. Pettaway, J. Slaton, R. Bevan-Thomas, 2002, The Journal of urology.

Tumor stage, vascular invasion and the percentage of poorly differentiated cancer: independent prognosticators for inguinal lymph node metastasis in penile squamous cancer.

P. Tamboli, C. Pettaway, J. Slaton, 2001, The Journal of urology.

Deoxyribonucleic acid ploidy enhances the cytological prediction of recurrent transitional cell carcinoma of the bladder.

H. Grossman, C. Dinney, J. Slaton, 1997, The Journal of urology.

Polysaccharide-K augments docetaxel-induced tumor suppression and antitumor immune response in an immunocompetent murine model of human prostate cancer

Hailing Lu, J. Slaton, M. Martzen, 2011, International journal of oncology.

Exposure to alkyllysophospholipids inhibits in vitro invasion of transitional cell carcinoma.

J. Slaton, S. Selman, J. A. Hampton, 1994, The Journal of urology.

Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer.

C. Dinney, K. Inoue, M. Bar‐eli, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Systemic administration of antisense oligonucleotides simultaneously targeting CK2α and α′ subunits reduces orthotopic xenograft prostate tumors in mice

G. Unger, B. Kren, V. Korman, 2011, Molecular and Cellular Biochemistry.

Induction of apoptosis by antisense CK2 in human prostate cancer xenograft model.

G. Unger, K. Ahmed, J. Slaton, 2004, Molecular cancer research : MCR.

Interleukin 8 expression regulates tumorigenicity and metastasis in human bladder cancer.

C. Dinney, K. Inoue, M. Bar‐eli, 2000, Cancer research.

Angiomyofibroblastoma‐like tumors (cellular angiofibroma)

M. Monga, J. Manivel, J. Slaton, 2006, International journal of urology : official journal of the Japanese Urological Association.

Increased aggressiveness of human prostate PC-3 tumor cells expressing cell surface localized membrane type-1 matrix metalloproteinase (MT1-MMP).

Michael J. Wilson, J. Slaton, D. Pei, 2009, Journal of andrology.

Gene therapy of human bladder cancer with adenovirus-mediated antisense basic fibroblast growth factor.

C. Wood, C. Dinney, K. Inoue, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Biosafety of in vivo adenovirus-p53 intravesical administration in mice.

R. Price, C. Dinney, D. R. Wilson, 2000, Urology.

Rationale for bladder‐sparing surgery in patients with locally advanced colorectal carcinoma

C. Dinney, J. Skibber, J. Slaton, 1999, Cancer.

The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy.

R. Millikan, C. Dinney, K. Inoue, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma.

C. Dinney, D. Hicklin, K. Inoue, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors

J. Slaton, 2006 .

Adenoviral-mediated gene therapy of human bladder cancer with antisense interleukin-8.

C. Wood, C. Dinney, K. Inoue, 2001, Oncology reports.

Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results.

P. Troncoso, C. Logothetis, K. Kamoi, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice.

C. Dinney, D. Hicklin, T. Shuin, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Early nasogastric tube removal combined with metoclopramide after radical cystectomy and urinary diversion.

L. Pisters, J. Slaton, S. Donat, 1999, The Journal of urology.

Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma.

C. Dinney, J. Slaton, D. Swanson, 1998, The Journal of urology.

Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule.

C. Dinney, I. Fidler, K. Inoue, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder.

C. Dinney, K. Inoue, T. Shuin, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Cyclosporine versus azathioprine: a 5-year followup of 200 consecutive cadaver renal transplant recipients.

J. Slaton, S. Selman, K. Kropp, 1994, The Journal of urology.

Association between lymph node density and disease specific survival in patients with penile cancer.

P. Tamboli, M. Munsell, P. Spiess, 2009, The Journal of urology.

Proximal ureteral stent migration: an avoidable complication?

J. Slaton, K. Kropp, 1996, The Journal of urology.

Percutaneous renal stone extraction: in vitro study of retrieval devices.

M. Monga, J. Slaton, Stephen J Lukasewycz, 2004, The Journal of urology.

Case report--sirolimus rescue therapy for refractory renal allograft rejection.

J. Slaton, B. Kahan, 1996, Transplantation.

Prognostic value of body mass index in patients undergoing nephrectomy for localized renal tumors.

A. Kamat, C. Rosser, L. Pisters, 2004, Urology.

Tenfibgen Ligand Nanoencapsulation Delivers Bi-Functional Anti-CK2 RNAi Oligomer to Key Sites for Prostate Cancer Targeting Using Human Xenograft Tumors in Mice

R. Vogel, G. Unger, B. Kren, 2014, PloS one.

Phase IIa, randomized placebo-controlled trial of single high dose cholecalciferol (vitamin D3) and daily Genistein (G-2535) versus double placebo in men with early stage prostate cancer undergoing prostatectomy.

H. Parnes, J. Kolesar, KyungMann Kim, 2016, American journal of clinical and experimental urology.

Potential Applications of Therapeutic Drug Monitoring of Sirolimus Immunosuppression in Clinical Renal Transplantation

J. Slaton, B. Kahan, K. Napoli, 1995, Therapeutic drug monitoring.

In vivo fluorescence imaging of an orthotopic rat bladder tumor model indicates differential uptake of intravesically instilled near-infrared labeled 2-deoxyglucose analog by neoplastic urinary bladder tissues

Daqing Piao, Carole A. Davis, Robert E. Hurst, 2017, BiOS.

Risk factors for upper tract recurrence in patients undergoing long-term surveillance for stage ta bladder cancer.

J. Slaton, J. K. Anderson, J. Premoli, 2006, The Journal of urology.

Phase II multi-center trial of optical coherence tomography as an adjunct to white light cystoscopy for intravesical real time imaging and staging of bladder cancer.

C. Lingley-Papadopoulos, S. Lerner, H. Sung, 2021, Urologic oncology.

A stage specific approach to tumor surveillance after radical cystectomy for transitional cell carcinoma of the bladder.

H. Grossman, C. Dinney, J. Slaton, 1999, The Journal of urology.

1870 ALVIMOPAN, A PERIPHERALLY ACTING MU-OPIOID RECEPTOR ANTAGONIST, ACCELERATES GASTROINTESTINAL RECOVERY AND DECREASES LENGTH OF HOSPITAL STAY AFTER RADICAL CYSTECTOMY

Sam S. Chang, R. Karnes, W. Sexton, 2013 .

Temperature activated deflection of a novel ureteroscopic laser fiber sheath.

M. Monga, J. Slaton, Courtney L. Lee, 2005, The Journal of urology.

Transitional cell carcinoma of the bladder with involvement of vasa deferentia.

B. Czerniak, J. Slaton, A. Kaufman, 1998, Journal of Urology.

Retransplantation following AHG-negative crossmatches

J. Slaton, B. Susskind, R. Kerman, 1997 .

Clinical presentation and outcome of high-grade urinary bladder leiomyosarcoma in adults.

C. Dinney, L. Levy, C. Rosser, 2003, Urology.

Maximizing ureteroscope deflection: "play it straight".

R. Clayman, M. Monga, J. Slaton, 2002, Urology.

Vascular organ procurement in the trauma population.

J. Morris, J. Slaton, D. Gibbs, 1989, The Journal of trauma.

WL-276, an antagonist against Bcl-2 proteins, overcomes drug resistance and suppresses prostate tumor growth.

J. Slaton, Liangyou Wang, Defeng Tian, 2008, Cancer research.